Loading patent…
AssigneesNovo Nordisk A/S, University of Genoa, Bristol-Myers Squibb Company
InventorsSØREN BERG PADKJAER, ALESSANDRO MORETTA, MARIELLA DELLA CHIESA, PASCALE ANDRE, LAURENT GAUTHIER, PETER ANDREAS NICOLAI RUMERT WAGTMANN
Estimating the term…
The present invention relates to novel compositions and methods for regulating an immune response in a subject. More particularly, the invention relates to specific antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects. The invention also relates to fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly in therapy, to increase NK cell activity or cytotoxicity in subjects.
1-7. (canceled)
An isolated antibody or antibody fragment that (a) cross-reacts with at least two different human KIR2DL polypeptides that each recognizes a different group of HLA-C class I allotypes, and (b) neutralizes the inhibitory activity of such polypeptides.
A composition suitable for human administration comprising a pharmaceutically acceptable excipient and an antibody or antibody fragment that (a) cross-reacts with at least two different human KIR2DL polypeptides that each recognizes a different group of HLA-C class I allotypes, and (b) neutralizes the inhibitory activity of such polypeptides.
Dependencies are inferred from the claim text.